Search for European Projects

8 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Novel therapeutic approaches for the treatment of cystic fibrosis based on small molecule transmembrane anion transporters (TAT-CF)

Start date: Jan 1, 2016, End date: Dec 31, 2018,

This project will develop an innovative therapeutic approach for the treatment of Cystic Fibrosis (CF). This condition originates from the defective function of the CFTR protein, a chloride and bicarbonate permeable transmembrane channel. This project will evaluate small molecules capable of facilitating the transmembrane transport of anions such as chloride and bicarbonate and will thus enable CF ...
Read Project

 8

 FINISHED 

Patient-specific stem cell-derived models for Alzheimer’s disease and related neurodegenerative disorders (STEMMAD)

Start date: Feb 1, 2013, End date: Dec 31, 2017,

Future treatment of incurable neurodegenerative disorders, including Alzheimer’s disease (AD), frontotemporal dementia (FTD), spinocerebellar ataxia (SCA), and Huntington’s disease (HD), has to be tailored to individual patients or cohorts of patients to obtain an optimal effect. The STEMMAD project is aimed to create a highly innovative international collaboration between 2 R&D intensive SME and ...
Read Project

 5

 FINISHED 

Collaboration on the Optimisation of Macromolecular Pharmaceutical Access to Cellular Targets (COMPACT)

Start date: Nov 1, 2012, End date: Oct 31, 2017,

Most biopharmaceuticals (BP) currently on the market are recombinant proteins which are parenterally administered. These would benefit from more patient-friendly routes of administration. Moreover, new classes of BP (e.g. siRNA, miRNA, DARPins) with specificity for intracellular targets hold promise but await the advent of efficient delivery systems before their potential can be realised into ther ...
Read Project

 22

 FINISHED 

The European non-coding RNA network (RNATRAIN)

Start date: Oct 1, 2013, End date: Sep 30, 2017,

"Non-coding RNA (ncRNA) is a new research field in rapid development. It holds the potential to explain many fundamental biological phenomena and there is a vast prospective for the development of ncRNA-derived diagnostic and therapeutic tools. Hence, biotech and pharmaceutical companies are actively looking into this unexplored territory for novel targets. Therefore, there is a substantial and un ...
Read Project

 11

 FINISHED 

Identification and validation of novel pharmaceutical drug targets for cardiovascular disease (CARTARDIS)

Start date: Oct 1, 2013, End date: Sep 30, 2017,

"Cardiovascular disease (CVD) is one of the major diseases in Europe and the Western world, killing over 2 million people per year in Europe alone and is the foremost cause of premature mortality and disability-adjusted life years, representing an annual economic cost of ∼€ 192 billion in direct and indirect healthcare expenses. The available therapies are insufficient to fulfill the need. The int ...
Read Project

 13

 FINISHED 

European Bank for induced pluripotent Stem Cells (EBISC)

Start date: Jan 1, 2014, End date: Dec 31, 2016,

EBiSC is designed to address the increasing demand by iPSC researchers for quality-controlled, disease-relevant research grade iPSC lines, data and cell services. Its goal is to demonstrate an operational banking and distribution service of iPSC lines after 3 years and to establish subsequently for Europe a centralised, not-for-profit bank providing all qualified users with access to scalable, cos ...
Read Project

 30

 FINISHED 

EUROpean consortium on NEUTralising antibodies using gp41 (EURONEUT-41)

Start date: Jan 1, 2008, End date: Mar 31, 2014,

There is now an increasingly solid body of scientific evidence which demonstrates that the binding of small molecular weight compounds, peptides and antibodies (Abs) to fusion-intermediate conformations of gp41 leads to an inhibition of HIV cell entry. The principal aim of this project is to exploit this information by establishing a platform where gp41-derived vaccine candidates will be designed ...
Read Project

 19

 FINISHED 

Biochemically Equivalent Substitutive Technology for Stem Cells (BEST-Stem cells)

Start date: Jul 1, 2009, End date: Dec 31, 2012,

Current technology to control embryonic and adult stem cell behaviour is dependent on conventional in vitro culture systems and crude factors such as serum and purified proteins, often sourced from vertebrate animal tissue. These factors contribute to variations in cell properties and differentiation potential which impact on the efficacy of cell culture. More worryingly these factors are potentia ...
Read Project

 8